Lupin Limited has informed the Exchange regarding a press release dated March 19, 2026, titled "Lupin Manufacturing Solutions Announces Expansion of Manufacturing Facility at Dabhasa, India".
LUPIN · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Lupin's wholly-owned subsidiary Lupin Manufacturing Solutions (LMS), a global CRDMO, announced a strategic expansion of its Dabhasa manufacturing facility in India. The expansion adds a new block to boost CRDMO capabilities along with two additional specialized units dedicated to peptide manufacturing. The move targets growing demand in complex therapeutics such as peptides and biologic ADCs, including protected amino acids. LMS currently has 250+ scientists and supports biopharma innovators from early development to commercial scale. Specific investment amount, capacity figures, and timelines were not disclosed in the press release.
The expansion strengthens Lupin's positioning in the high-growth complex peptide and CRDMO space, which could support future revenue diversification beyond generics. However, since no capex quantum or revenue projections were shared, near-term stock impact is likely to be modest and sentiment-driven rather than earnings-driven.